<DOC>
	<DOCNO>NCT00645502</DOCNO>
	<brief_summary>The primary objective study demonstrate bioequivalence , respect risperidone active moiety , single oral dose risperidone give 4 mg orally-disintegrating tablet 4 mg conventional RISPERDAL tablet . In addition , tolerability safety document .</brief_summary>
	<brief_title>Bioequivalence Study Comparing 2 Formulations 4 mg Risperidone Tablet .</brief_title>
	<detailed_description>This single-center , open , randomize , 2-way crossover bioequivalence study 40 subject schizophrenia schizoaffective disorder . The study consist 2 treatment period , 5 day per period . The subject receive single 4 mg RISPERDAL conventional tablet period 1 single 4 mg orally-disintegrating tablet period 2 ; orally disintegrate tablet period 1 conventional tablet period 2 . A washout period least 10 day Day 1 Period 1 Day 1 Period 2 separate 2 treatment . In treatment period plasma concentration drug measure . Serial blood collection make begin 0 hour ( immediately study drug administration ) continue 96 hour study drug administration period . Safety evaluate throughout study use physical examination , electrocardiogram recording ( ECG ) , clinical laboratory testing ( hematology , serum chemistry , urinalysis ) , vital sign measurement , pregnancy testing , drug screening , monitor adverse event . The study approximately 6 week long ( include screen period ) . Subjects enter study facility 3 day first administration study medication Day 1 first period . They remain facility study-related procedure complete Day 5 second study period , period approximately 18 day . 4 mg risperidone ( either conventional tablet orally-disintegrating tablet ) , single dose , oral intake</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients diagnosis schizophrenia subtype normal weight define Body Mass Index range 18.0 35.0 , extreme include For Informed consent form sign patient legally acceptable representative available healthy basis pretrial physical examination , medical history , electrocardiogram ( ECG ) , result blood biochemistry hematology test urinalysis carry less 3 week first dose study medication take Patients mental disorder schizophrenia schizoaffective disorder , accord DSMIV Patients receive oral risperidone paliperidone within 14 day first drug administration , Risperdal Consta within 100 day first drug administration paliperidone palmitate within 10 month first drug administration Patients used medication know hepatic enzyme inducer inhibitor le 2 week prior first drug administration Patients history allergic reaction risperidone excipients Patients diagnosis alcohol substance abuse Patients history clinically relevant cardiac arrhythmia 's , bronchospastic cardiovascular disease , diabetes mellitus , thyrotoxicosis , parkinsonism , drug allergy Female patient pregnant breastfeed childbearing potential without adequate contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Orally-disintegrating tablet</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>